Clinical trial · Interventional
Human Papillomavirus Epidemiology in Nigeria
Epidemiologic and Molecular Features of Cervical Cancer in Nigeria - Project Itoju (Care)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Background: * Cervical cancer is caused by persistent infection of the lining of the cervix with some kinds of human papillomaviruses (HPV). These HPV infections are distantly related to the viruses that cause warts on the skin. Like common wart viruses, most women who have cervical infections with HPV resolve the infections within 2 years without any need for treatment. Cervical infections that do not go away may cause disease that can turn into cancer after many years. * Only one study has been done in Nigeria to learn how many women have HPV infection. The results of the study differed from most other studies in the world because older women were much more likely to be infected. This study with learn whether the results found in the previous study are true in Irun also, the site of the current study. Objectives: * To examine the age distribution of HPV infection and relationship to cancer of the cervix among Nigerian women. * To understand how different screening methods, including HPV testing, could best reduce the risk of cervical cancer in Nigerian women. Eligibility: \- Women residing in Irun, Nigeria, who are 15 years of age or older. Design: * Participants complete a brief questionnaire related to demographics, household and living conditions and a longer survey with questions related to reproductive history, family history, illnesses, stressful life events and sexual history (U. of Michigan collaboration). * Participants have a cervical examination, HPV test, Pap test and blood test. * Women whose tests show they are infected with HPV or have cervical disease will do the following: * see a doctor and have cervical biopsies of all white abnormal areas (removal of a small tissue sample from the cervix) * have photographs of the cervix taken * have a cervical scraping for a new kind of HPV test. * Some women with normal test results are also asked to see a doctor to check the validity of the testing * Women with cervical disease receive treatment by a specialist and remain in the program until treatment is successfully completed or a final diagnosis is reached. * Participants may be contacted for followup up to 5 years after the final diagnosis is made.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Intraepithelial Neoplasia | Cervical Intraepithelial Neoplasia | ONTOLOGY_EXACT | 0.98 |
| Human Papillomavirus 16 | — | UNRESOLVED | — |
| Human Papillomavirus 18 | — | UNRESOLVED | — |
| Uterine Cervical Neoplasms | Cervical Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EVA System | Device | — | UNRESOLVED |
| OncoE6 | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Women referred to colposcopy clinic
- description
- Triage tests for diagnosis of cervical pre-cancer amongHPV positive women
- interventionNames
- Device: OncoE6
- Device: EVA System
Primary outcomes (1)
- measure
- Sensitivity of triage methods
- timeFrame
- cross-sectional
- description
- Cervical Histopathology
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 30 Years
- Maximum age
- 49 Years
Show eligibility criteria text
* INCLUSION CRITERIA: * Females who are 15 years to 99 years of age EXCLUSION CRITERIA: * Previous hysterectomy * Current pregnancy * Inability to give informed consent
References
Publications (3)
- BACKGROUNDClarke MA, Gage JC, Ajenifuja KO, Wentzensen NA, Adepiti AC, Wacholder S, Burk RD, Schiffman M. A population-based cross-sectional study of age-specific risk factors for high risk human papillomavirus prevalence in rural Nigeria. Infect Agent Cancer. 2011 Jul 29;6:12. doi: 10.1186/1750-9378-6-12. PMID 21801395
- BACKGROUNDGage JC, Ajenifuja KO, Wentzensen NA, Adepiti AC, Eklund C, Reilly M, Hutchinson M, Wacholder S, Harford J, Soliman AS, Burk RD, Schiffman M. The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: implications for screen-and-treat strategies. Int J Cancer. 2012 May 1;130(9):2111-7. doi: 10.1002/ijc.26211. Epub 2011 Aug 5. PMID 21630264
- BACKGROUNDGage JC, Ajenifuja KO, Wentzensen N, Adepiti AC, Stoler M, Eder PS, Bell L, Shrestha N, Eklund C, Reilly M, Hutchinson M, Wacholder S, Castle PE, Burk RD, Schiffman M. Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria. Int J Cancer. 2012 Dec 15;131(12):2903-9. doi: 10.1002/ijc.27563. Epub 2012 Apr 27. PMID 22473652